drugset
drugset / Trial / NCT05865171

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

NCT05865171 ↗

Phase 1 Completed 16 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.

Timeline

Start
2023-06-12
Primary completion
2024-06-12
Completion
2024-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Inaxaplin Small molecule — Oral

Indications

impaired renal function disease